Thrills, pills, & VC bills: What will it take to unleash innovation in the world of drug development?

Drug development and rapid innovation are unlikely bedfellows. Drug development is, by its very nature, a long-winded, wieldy, hyper-expensive process. However, the integration of artificial intelligence, high-throughput screening techniques, and advanced computational modelling has catalysed the identification of potential drug candidates and expedited the prediction of their efficacy and safety profiles. Are we finally entering an era where the once-distant notions of drug development and rapid innovation are becoming increasingly intertwined? And what will it take for the industry to fully harness the potential of novel tools and strategies to address unmet medical needs in a more efficient and agile manner?